ClinicalTrials.gg

Gastroesophageal Reflux clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 1,216 studies for Gastroesophageal Reflux across more than 10 countries. 204 are recruiting or about to start. 871 of them are mainly about Gastroesophageal Reflux (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its 3 narrower conditions too, such as Laryngopharyngeal Reflux: 1,307 studies, 221 open.

ClinicalTrials.gov finds 1,565 studies for Gastroesophageal Reflux. How that becomes 1,216 here

This page counts the studies the registry files under Gastroesophageal Reflux, and those it files under no condition that list Gastroesophageal Refluxthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 17, 2026. How condition pages count

  1. 1,565Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −85Filed under a narrower condition, counted on its own pageLaryngopharyngeal Reflux 33 · Non-Erosive Reflux Disease 28 · Respiratory Aspiration of Gastric Contents 21
  3. −9List Gastroesophageal Reflux as a condition, but the registry did not file them under itMost often written as “Hiatal Hernia With Gastroesophageal Reflux Disease” (3), “Non-Erosive Gastro-Esophageal Reflux Disease” (2), and “Gastroesophageal Reflux Disease With Hiatal Hernia” (1). The registry filed them under other conditions only, most often Hernia, Hiatal (3) and Heartburn (3).
  4. −258Match it another way44 name it in the title, 3 in a keyword, and 211 by a synonym or other text the search reads.
  5. 1,213Counted here and found by its search32 of them list Gastroesophageal Reflux in their own words; the registry filed them under no condition.
  6. +3
    Counted here, but its search does not find them
  7. 1,216The count on this page

Status

Completed
700
Status unknown
140
Recruiting
134
Terminated
81
Not yet recruiting
55
Withdrawn
54

Phase

Phase 3
125
Phase 4
118
Phase 1
85
Phase 2
85
Early Phase 1
6

Where

United States
421
Italy
78
Germany
70
France
62
China
56
Korea, Republic of
56

Who develops what

Add Gastroesophageal Reflux to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 12 programs from 10 companies, 11 with this as their studies’ main aim; 2 with a live phase 3 study; 1 primary completion in the next 12 months. Compare Yuhan, Daewon Pharmaceutical and HK inno.N here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
EsomeprazoleRecent, repeated
Evidence
  • NCT07931521 · Daewon Pharmaceutical Co., Ltd. · Phase 3 · comparator · “Esomeprazole 40mg” · registered Oct 2026
  • NCT05701540 · HK inno.N Corporation · Phase 4 · live · comparator · “Esomeprazole” · registered Jan 2023
  • NCT04282954 · Jeil Pharmaceutical Co., Ltd. · Phase 2 · comparator · “Esomeprazole 40mg” · registered Feb 2020
  • NCT03184324 · Daewoong Pharmaceutical Co. LTD. · Phase 2 · comparator · “Esomeprazole” · registered Jun 2017
  • NCT02860624 · Joincare Pharmaceutical Group Industry Co., Ltd. · Phase 3 · comparator · “40mg esomeprazole” · registered Jul 2016
AstraZeneca71% of its industry studiesUS: off-patent, 34 generics marketedEU: HALEON (EMA 2013)22 studies
LansoprazoleRecent, repeated
Evidence
  • NCT07732075 · Jeil Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Lansoprazole 15mg” · registered Jul 2026
  • NCT07037875 · Cinclus Pharma Holding AB · Phase 3 · comparator · “Lansoprazole 30 mg Once Daily (QD)” · registered Jun 2025
  • NCT03355170 · Neutec Ar-Ge San ve Tic A.Ş · Phase 4 · comparator · “Lansoprazole” · registered Nov 2017
  • NCT01509261 · Il-Yang Pharm. Co., Ltd. · Phase 3 · comparator · “Lansoprazole” · registered Jan 2012
  • NCT00637845 · AstraZeneca · Phase 4 · comparator · “Lansoprazole” · registered Mar 2008
Takeda36% of its industry studiesUS: off-patent, 13 generics marketed22 studies

4 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
vonoprazanApproved: US 2023☆ Track1 live phase-3 study: NCT07752407Phathom Pharmaceuticals, Inc.
zastaprazan☆ Track1 live phase-3 study: NCT07732075Jeil Pharmaceutical Co., Ltd.

The 2 in phase 3 with the nearest primary completion, of 12 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 20 Oct 2027 est.vonoprazan · Phathom Pharmaceuticals, Inc. · Phase 3 main aimNCT07752407 A Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for Relief of Episodic Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease Through 24 Weeks — primary endpoint: Percentage of Treated Heartburn Episodes Achieving Complete Relief at 2 Hours and Sustained Relief for 24 Hours up to Week 12 · 500 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Gastroesophageal Reflux studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Proton pump inhibitors (PPIs) 6 open · H2 blockers 2 open · Antiemetics 1 open · Serotonin receptor agonists 1 open · SSRIs 1 open

Coming up

68studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 134 Gastroesophageal Reflux studies recruiting now, 58 (43%) set no upper age limit and 53 (40%) stop at 75 or younger. 22 (16%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 20 (15%) take healthy volunteers.

Recruiting studies that take each age, of 134
AgeWomenMen
109 (7%)9 (7%)
18106 (79%)106 (79%)
30117 (87%)117 (87%)
40119 (89%)119 (89%)
50119 (89%)119 (89%)
65110 (82%)110 (82%)
7592 (69%)92 (69%)
8571 (53%)71 (53%)

Across all 1,216 studies, recruiting or not: 46% stop at 75 or younger and 29% at 65; 18% take children; <1% are for women only and 1% for men only; 21% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Gastroesophageal Reflux studies take

Of 34 phase 1 interventional studies under Gastroesophageal Reflux, half reached primary completion within 4 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 14 mo2–10 · 34 studies4 mo1–6 · 28 studies—
Phase 215 mo13–52 · 14 studies——
Phase 319 mo11–49 · 21 studies——
Phase 428 mo15–53 · 30 studies——
Interventional, no phase32 mo12–68 · 228 studies33 mo21–59 · 34 studies31 mo12–68 · 194 studies
Observational45 mo17–134 · 117 studies—57 mo18–167 · 95 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 19, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 1,216. Browse all 1,216 → or search them.